Zupar – a powerful anti-inflammatory medication

 

Zupar.Introduction

 

The fire of itself is a normal abient response to the tissue damage and is a mechanism of removing of the damaging agent and the healing of the affected tissues in order to recover the functions. However, in the case of some medical conditions a number of the protective mechanisms are ineffective. In such cases, the prescription of the meds that arrest fire is necessary.

In addition to the corticosteroids – the most powerful negative catalyst of fire, the non-steroidal anti-inflammatory drugs (NSAIDs) have the significant anti-inflammatory effects. One of such effective NSAID is Zupar.

 

Zupar. What is the Preparation?

 

Zupar is a combined synthetic drug. The main active ingredients of Zupar are ibuprofen and acetaminophen.

Zupar combines perfectly two effective complementary and synergistic components: ibuprofen and acetaminophen. It is effective and safe combined NSAID with a double-quick impending of the clinical effects. Such combination provides immediate analgesic end point, followed by a pronounced anti-inflammatory effect.

The clinical trials have shown that Zupar allows faster and more effective pain relief than ibuprofen as a single drug in a dose of 400 mg.

Acetaminophen is characterized by a rapid and pronounced analgesic effect, and ibuprofen is characterized by a powerful anti-inflammatory effect, combined with a strong analgesic effect. This synergistic combination of the medication can reduce pain, cut short fever as well as promote powerful anti-inflammatory effect.

 

 

Zupar. The Therapeutic Indications

 

For adults:

 

Pain syndrome of the average intensity;

Traumatic fire of the soft tissues and musculoskeletal system (bruises, sprains, dislocations, fractures, etc.);

Postoperative period;

Tuberculosis;

Toothache;

Neuralgia;

Myoneuralgia;

Lumbago;

Fibrosis;

Tendinous synovitis;

Headache;

Febrile syndrome;

Arthral syndrome (rheumatoid arthritis, osteoarthritis, Marie-Strumpell disease, gout);

Sinusitis;

Tonsillitis.

For children (as the adjuvant):

Tonsillitis;

Acute infectious-inflammatory diseases of the upper respiratory tract (sore throat, inflammation of the trachea, laryngitis).

 

 

Zupar. The Advantages

a)      Two active ingredients: ibuprofen and paracetamol;

b)      Pluripotential;

c)      Quick effect;

d)     Strong synergistic effect;

e)      For all categories of the patients;

f)       Long-term effect.

g)      Duration of action.

 

 

Zupar. The Treatment Efficacy

 Zupar-Treatment-Efficacy

 

As it can be seen from the picture, there is no need to have a recure, if a patient takes Ibuprofen + Paracetamol. In other words, the medication Zupar shows the highest efficacy in the treatment of the above mentioned diseases. More than that, the preparation is approved for use by US Food and Drug Administration (FDA).

 

 

Zupar. The Recommendations for Administration

 

Zipar has to be taken per os. Adults: 1 tablet 3-4 times a day after meal, the maximum dose is 2 tablets 3 times a day. Children, who weight more than 30 kg per 1/2 tablets 3 times a day.

 

 

Zupar. The Feedbacks

 

I take this med, when I have the various pains. It reduces the temperature in a matter of minutes. I encourage you to use Zupar!

Henrietta, 37 y.

 

Zupar is a very good, when there are the inflammatory conditions, it relieves headaches, toothaches and joint pain.

Ted, 45 y.

 

My attending medical doctor prescribed Zupar as analgesic. I took it as frontal, and in 10 minutes headache was over. It is good that the med is reasonable, and I do not throw down.

Pamela, 26 y.

 

I had to say goodbye to my wisdom tooth, it teethed hard and I pulled it out. In a couple of hours the pain was severe!!!

I have a baby and I did not want to give up breast-feeding. The pediatrician suggested this medication. It helped me in 10 minutes and it did not harm my baby.

Diana, 31 y.

Be the first to comment on "Zupar – a powerful anti-inflammatory medication"

Leave a comment

Your email address will not be published.


*